Drug General Information
Drug ID
D0R5FO
Former ID
DNC009232
Drug Name
KYS-05057
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529566]
Formula
C32H33N5O3S
Canonical SMILES
CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CNC(=O)CC3C4=CC=CC<br />=C4N=C(N3C5=CC=CC=C5)N(C)C
InChI
1S/C32H33N5O3S/c1-23-13-19-27(20-14-23)41(39,40)35-25-17-15-24(16-18-25)22-33-31(38)21-30-28-11-7-8-12-29(28)34-32(36(2)3)37(30)26-9-5-4-6-10-26/h4-20,30,35H,21-22H2,1-3H3,(H,33,38)
InChIKey
BUARRUHMMCHOQJ-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Voltage-dependent T-type calcium channel alpha-1G subunit Target Info Inhibitor [529566]
KEGG Pathway MAPK signaling pathway
Calcium signaling pathway
Circadian entrainment
Type II diabetes mellitus
PANTHER Pathway Endogenous cannabinoid signaling
GABA-B receptor II signaling
Nicotine pharmacodynamics pathway
Pathway Interaction Database Regulation of nuclear beta catenin signaling and target gene transcription
PathWhiz Pathway Muscle/Heart Contraction
Reactome NCAM1 interactions
WikiPathways NCAM signaling for neurite out-growth
Nicotine Activity on Chromaffin Cells
References
Ref 529566Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. Epub 2008 Jun 14.T-type Ca2+ channel blockers suppress the growth of human cancer cells.
Ref 529566Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. Epub 2008 Jun 14.T-type Ca2+ channel blockers suppress the growth of human cancer cells.